PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642,280 | +6.6% | 38,506 | +76.6% | 0.00% | – |
| Q2 2023 | $602,365 | -53.4% | 21,809 | -61.2% | 0.00% | -100.0% |
| Q1 2023 | $1,292,968 | +112.0% | 56,216 | +0.6% | 0.00% | – |
| Q4 2022 | $609,770 | +600.9% | 55,891 | +443.2% | 0.00% | – |
| Q3 2022 | $87,000 | -71.0% | 10,289 | -72.9% | 0.00% | – |
| Q2 2022 | $300,000 | -58.7% | 37,956 | +23.6% | 0.00% | – |
| Q1 2022 | $727,000 | -81.5% | 30,700 | -73.2% | 0.00% | -100.0% |
| Q4 2021 | $3,922,000 | +282.6% | 114,696 | +98.3% | 0.00% | – |
| Q3 2021 | $1,025,000 | +251.0% | 57,854 | +299.7% | 0.00% | – |
| Q4 2020 | $292,000 | +12.7% | 14,473 | +9.1% | 0.00% | – |
| Q3 2020 | $259,000 | +197.7% | 13,268 | +2.5% | 0.00% | – |
| Q2 2018 | $87,000 | -62.5% | 12,945 | +18.1% | 0.00% | -100.0% |
| Q3 2016 | $232,000 | – | 10,964 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |